Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude/SRI International

This article was originally published in The Gray Sheet

Executive Summary

Collaborating on development of St. Jude's BioXenoGraft, a bioprosthesis "which would have improved durability over conventional tissue valve products" and avoid the need for anticoagulants associated with mechanical valves, St. Jude says. SRI International, a nonprofit corporation chartered by the state of California, will apply its "expertise in implantable bioprosthetic devices" to the development of the product. The work will complement a project between St. Jude and Advanced Tissue Sciences to use ATS' tissue engineering technology to develop tissue heart valves with improved biocompatibility and durability ("The Gray Sheet" Feb. 21, I&W-1)

You may also be interested in...



Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

UsernamePublicRestriction

Register

MT002867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel